Accelus key facts
as of Oct 2026- Developer of medical implants designed to focus on expandable interbody technology for spine surgery.
- Accelus is valued at approximately $342.0M as of Oct 2026 (last reported valuation).
- It has raised $68.2M; the latest was Buyout/LBO in Aug 2025.
- Notable investors include Kinled Holding, Eastward Capital Partners, Trog Hawley Capital, Concord Health Partners.
- Status: Privately Held (backing).
Accelus's last reported valuation, Jul 2022. Nothing priced has surfaced since.
- ·Watch Accelus: the Monday email on marks, rounds and moves
Accelus funding rounds
No funding rounds for Accelus are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Accelus valuation
Accelus's last reported valuation was $342 million in Jul 2022. No priced round, secondary trade or fund mark has surfaced since.
Accelus investors
4 investors are on record for Accelus, including Kinled Holding, Eastward Capital Partners, Trog Hawley Capital and Concord Health Partners.
About Accelus
Developer of medical implants designed to focus on expandable interbody technology for spine surgery. The company's implants are a bi-directional expandable cage with the strength and rigidity of a monolithic implant, enabling doctors and orthopedic surgeons to treat height, weight, or lordosis problems.
- Sector
- Healthcare
- HQ
- Palm Beach Gardens, FL, United States
- Founded
- 2016
- Employees
- 68
- Website
- accelusinc.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.